A recent paper by Fabio Zattoni, Associate Professor at Urology Clinic, University of Padua, was mentioned by Juan Gómez Rivas, Associate Professor at The Complutense University of Madrid, on X:
Authors: Fabio Zattoni, Giorgio Gandaglia, Roderick van den Bergh, Fabrizio Dal Moro, Giacomo Novara et al.
“Patients with a positive mpMRI (PI-RADS ≥3) but negative target and systematic biopsies still face risks of prostate cancer (26.8%) and clinically significant prostate cancer (19.3%). Follow-up strategies matter!
- Best outcomes: repeat mpMRIs and biopsy based on clinical/radiological triggers (96% csPCA-free at 2 years).
- Predictors: age, prostate volume, PI-RADS score, ASAP, and biopsy core count.
Tailored follow-up is essential for managing these high-risk cases.”
More posts featuring Juan Gómez Rivas.